Clinical Trial Update: Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating dosing interval of adalimumab in Crohn's disease patients in remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Crohn Disease in Remission

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Crohn Disease in Remission, Crohn Disease | Phase 4 | Status: UNKNOWN